TAK 058

Drug Profile

TAK 058

Alternative Names: ENV-8058

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Envoy Therapeutics
  • Developer Takeda
  • Class Antidementias; Antipsychotics
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in USA (PO, Liquid)
  • 01 Dec 2015 Phase-I clinical trials in Schizophrenia (Combination therapy) in USA (PO)
  • 01 Dec 2015 Takeda completes a phase I trial in Healthy volunteers in USA (NCT02389881)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top